BioKine Therapeutics Ltd.

biokine.com

High-Tech Company

Graduated from: ITEK

TECH VERTICALS

Cancer, Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2000
Number of Employees	6
Reg. Number:	abCDe

DESCRIPTION

Biokine Therapeutics is a clinical stage biopharmaceutical company developing novel drugs to treat Cancer and Inflammation. Biokine focuses its drug research specifically on targeting the tumor microenvironment.
Biokine has completed more than 17 years of R&D, and its leading product, BKT140/BL-8040: best-in-class CXCR4 antagonist is a bio-stable 14-residue cyclic peptide with high affinity (1- 2 nM, compare to 84nM of plerixafor) and a slow off-rate of the receptor. Biokine has recently demonstrated in a Phase I study in healthy volunteers, that single dose of the CXCR4 antagonist BL-8040 induces a rapid and robust mobilization and mega dose collection of human CD34+ stem and progenitor cells. A Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of BM stem cells from the peripheral blood circulation is currently conducted. Moreover BL8040 which has the ability to reshape the microenvironment of tumors, is now in Phase IIb clinical trials for the treatment of Acute Myeloid Leukemia (AML), and is tested in multiple cancer indications together with immune check point inhibitors such as Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx on September 2012 and is being developed in the clinic by Biokine together with BiolineRx Ltd

TECHNOLOGY

Screening System/ Platform, Therapeutics

Products and Phases

Product	Phase
ChemoHit	Phase II
ChemoHit is a screening system platform technology to find antagonists and agonists to chemokine activity.
Peptein
Peptein This is a unique proprietary system designed to identify inhibitors of intracellular pathways. Unlike conventional drug discovery approaches, Peptein™ can target the entire receptor pathway, rather than just a single protein, facilitating rapid and selective identification of potential leads.
ReceptorHit
ReceptorHit provides a platform for screening for known and unknown GPCR antagonists and agonists. ReceptorHit™ uses a unique presentation methodology of GPCRs, and a biologically-active screening methodology.
BL8040	Phase III
BL8040 which as the ability to reshape the microenvironment of tumors is now in Phase IIb clinical trials for the treatment of Acute Myeloid Leukemia (AML), and is tested in multiple cancer indication together with immune check point inhibitors such as Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx on September 2012 and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX).
BKT-P46
The chemokines MCP-1 and RANTES are involved in the progression and development of inflammatory and autoimmune diseases as well as cancer. Using the ChemoHit™ platform technology, Biokine has identified the promiscuous chemokine binding peptide BKT-P46. BKT-P46 inhibits the bioactivity of multiple chemokines including MCP-1 and RANTES
BKT 300
BKT300 is a novel anti-cancer metastasis, synthetic small molecule, for the oncology market. BKT300 selectively induces arrest of cancer cells at G2M, before cytokinesis, at the prophase I cell cycle phase, and induces their apoptotic cell death through caspase-3 pathway. The results demonstrate that BKT300 interferes indirectly with tubulin organization in tumor cells. Preliminary data indicate that BKT300 regulates key component of the cell cycle pathway which is expressed only in tumor cells. In normal cells as well as in some tumor cells that do not response to BKT300, this pathway is absent. BKT300 selectively induces the arrest of leukemic, ovarian, pancreatic, lung, and prostate cancer cells at G2M and induces their rapid apoptotic cell death in vitro and in vivo. BKT300 had no apparent toxicity in mice injected IV with 40 mg/Kg for up to two weeks.
BKT130
BKT130 is a novel antibody which binds at high affinity to CCL2, CCL5, CXCL10, and CCL20 and inhibits their function. BKT130 showed a significant Inhibition of migration of immune cells in response to CCL2, CCL5, CXCL10, and CCL20. In vivo, BKT130 significantly inhibited the migration of monocytes and disease progression in a variety of animal models for autoimmunity and inflammatory diseases such as Multiple Sclerosis, Rheumatoid Arthritis, and Age Related Macular Degeneration (AMD). In AMD, BKT130 blocked the recruitment of macrophages and angiogenesis. In melanoma and pancreatic mouse models BKT130 showed an anti-tumor as single agent. Preliminary results suggest very low toxicity together with prolonged PK profile. Biokine is planning to initiate phase I/II clinical study in cancer patients within the next three years.

	TARGET MARKETS
	Patients with inflammatory disorders and cancer metastasis, Pharmaceutical Companies, Hospitals.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Patent Attorneys

CONTACT INFO

Expand / Collapse All

Main Address: Rehovot, Israel

Address	Bldg.13 A, Weizmann Science Park
POB	2213
City	Rehovot
Country	Israel
Zip	76120

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Prof. Amnon Peled	CEO, CSO & Co-Founder
Dr. Orly Eizenberg	VP, R&D & Co-Founder
Dr. Michal Abraham-Karni	Head of Pre-Clinical Development

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Medical & Scientific Planning Manager, Meytav Technological Incubator
abC Defghij	Board Member	Founder, Ethrog Biotechnologies
abC Defghij	Board Member	CSO & Co-Founder , BioKine Therapeutics
abC Defghij	Board Member	VP, Clal Biotechnology Industries (CBI) Ltd.
abC Defghij	Board Member	Founder, Meyuhas & Partners LLB
abC Defghij	Board Member	Life Science Holdings Ltd

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Third Round

Mar. 06, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe	Holds 25% of the company
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Second Round

Jan. 10, 2007

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe

First Round

Dec. 01, 2003

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe	Invested through CureTech
abC Defghij	Private Investor	abCDe

Seed - Extended

Oct. 01, 2001

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed

Aug. 01, 2000

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	R&D Grant.
abC Defghij	Incubator	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2018

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Mar. 18, 2009

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Apr. 24, 2006

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-Lateral R&D Program	abCDe

R&D Grant

Jun. 05, 2005

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Bi-Lateral R&D Program	abCDe

Last Updated:	abCDe
IVC Number:	abCDe